Teva's S&P credit rating upgraded to 'BB+' and Moody's outlook revised to positive, reaching investment-grade status.
In Tel Aviv, Israel, on December 24, 2025, Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) revealed that S&P Global Ratings has boosted Teva’s long-term issuer credit rating to ‘BB+’ from ‘BB’, maintaining a stable outlook. Moody's Ratings Agency also affirmed Teva's B1a rating and changed the outlook to positive from stable. These developments signify a notable advancement for Teva in its pursuit of attaining investment-grade standing.
Source: Unusual Whales The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments